Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 5/20 | 0.60 |
| ▸ | GFER | P55789 | 1/20 | 0.55 |
| ▸ | SHMT2 | P34897 | 4/20 | 0.54 |
| ▸ | SHMT1 | P34896 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | RHOC | P08134 | 1/20 | 0.51 |
| ▸ | RHOA | P61586 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8424602 | 0.86 | KDM4E (0.71) | TP53SHMT2SHMT1KDM4ELMNA | |
| SCHEMBL21560039 | 0.86 | SHMT2 (0.72) | TP53GFERSHMT2SHMT1KDM4E | |
| SCHEMBL8240059 | 0.84 | SHMT1 (0.60) | TP53GFERSHMT2SHMT1KDM4E | |
| SCHEMBL21560017 | 0.84 | GAA (0.71) | TP53GFERSHMT2SHMT1KDM4E | |
| SCHEMBL12608909 | 0.82 | GFER (0.62) | TP53GFERKDM4ETHRBLMNA | |
| SCHEMBL12608910 | 0.82 | TP53 (0.55) | TP53GFERSHMT2SHMT1KDM4E | |
| SCHEMBL27344271 | 0.81 | ALDH1A1 (0.64) | TP53GFERKDM4ETHRBLMNA | |
| Fenclozic Acid SCHEMBL27104 | 0.80 | LMNA (0.73) | TP53GFERSHMT2SHMT1KDM4E | |
| SCHEMBL21559996 | 0.80 | SHMT1 (0.72) | TP53GFERSHMT2SHMT1KDM4E | |
| SCHEMBL20255618 | 0.80 | SHMT1 (0.72) | TP53GFERSHMT2SHMT1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7335725-B2 | Lipopeptides as antibacterial agents | CUBIST PHARMACEUTICALS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-20050203006-A1 | Novel lipopeptides as antibacterial agents | MERCK SHARP & DOHME CORP. | 2005-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203006-A1 | Novel lipopeptides as antibacterial agents | CLPTM1, NGLY1, VIP | TP53 3685/4885GFER 1883/4885SHMT2 3771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.